AstraZeneca

Kidneys
#AstraZeneca #Chronic kidney disease (CKD) #Kidney disease #National Institute for Health and Care Excellence (NICE)

More patients to become eligible for chronic kidney disease treatment 

The UK National Institute for Health and Care Excellence (NICE) has published updated Final Draft Guidance recommending AstraZeneca’s Forxiga (dapagliflozin) as an option to treat chronic kidney disease (CKD) in adults in certain cases. This is the case if: It is an add-on to optimised standard care including the highest… Read More

#News

Map of Europe
#AstraZeneca #European Commission #Lymphoma #Oncology #Phase III trial

Calquence plus chemoimmunotherapy approved in the EU

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the European Union (EU) for previously untreated mantle cell lymphoma (MCL).  It is approved in patients who are not eligible for autologous stem cell transplant.  The approval by the European Commission was based on positive results from… Read More

#News #Regulatory

#Artificial intelligence (AI) #AstraZeneca #Foundational model #Oncology

Partners to build largest multimodal oncology foundation model

AstraZeneca, Tempus AI and Pathos AI have entered a multi-year, strategic collaboration to build a multimodal foundation model in oncology.  The model will be used to gather biological and clinical insights, discover novel drug targets, and develop therapeutics for the broader oncology community.  Upon completion, the model will be shared… Read More

#Business & Investment #Cancer Research #News

Cholesterol test
#AstraZeneca #Cardiovascular disease #Cholesterol #Clinical trial

PCSK9 inhibitor demonstrates significant cholesterol reduction

Positive results from the PURSUIT Phase IIb trial for AstraZeneca’s AZD0780 have demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of standard-of-care statin therapy.  AZD0780 is an investigational once-daily oral PCSK9 inhibitor for patients currently not reaching their LDL-C lowering goal despite… Read More

#News

Bladder cancer
#AstraZeneca #Bladder cancer #FDA #Monoclonal antibodies #Oncology

Imfinzi approval a ‘breakthrough’ for muscle-invasive bladder cancer

AstraZeneca’s Imfinzi (durvalumab) has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with muscle-invasive bladder cancer (MIBC).  It is approved in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the bladder). … Read More

#News #Regulatory

Beijing city centre
#AstraZeneca #China #Investment

AZ invests $2.5bn in R&D centre and collaborations in Beijing 

AstraZeneca has announced an investment of $2.5 billion in Beijing to establish its sixth global strategic R&D centre, together with further research and manufacturing agreements in China.   This investment over the next five years is part of a strategic partnership with the Beijing Municipal Government and the Beijing Economic-Technological Development… Read More

#Business & Investment #News

#AstraZeneca #Cell therapy #EsoBiotec #Mergers and acquisitions

AstraZeneca acquires in vivo cell therapy developer

EsoBiotec, a biotechnology company developing in vivo cell therapies, is to be acquired by AstraZeneca.  AstraZeneca will make an initial payment of $425m on deal closing, and up to $575m in contingent consideration based on development and regulatory milestones.  The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform is designed to empower… Read More

#Business & Investment #News

Breast cancer
#AstraZeneca #Breast cancer #Cancer research #NHS Scotland #Scottish Medicines Consortium (SMC)

SMC accepts AstraZeneca’s breast cancer treatment

AstraZeneca’s Lynparza (olaparib) has been accepted for use within NHS Scotland by the Scottish Medicines Consortium (SMC) to treat adults with HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations after chemotherapy. Breast cancer prevalence In Scotland, nearly 5,000 people are diagnosed with breast cancer each… Read More

#Cancer Research #News

#Artificial intelligence (AI) #AstraZeneca #Innovate UK #Pioneer Group #The Medical Research Council

Industry and academic partners promote AI innovation

Pioneer Group, Innovate UK, The Medical Research Council (MRC) and AstraZeneca have joined forces to deliver the AI in Health Accelerator 2024/2025 Programme.  The Accelerator is designed to help entrepreneurs confidently market their AI-driven healthcare solutions and accelerate novel technology development time to market.   The partners will collaborate across all… Read More

#Business & Investment #News

Cancer cells
#Antibody drug conjugate (ADC) #AstraZeneca #Breast cancer #Daiichi Sankyo #FDA #Oncology

FDA approved ADC improves breast cancer survival by 37%

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan-dlnk (Datroway) a Trop-2-directed antibody and topoisomerase inhibitor conjugate, as a treatment for breast cancer.  The decision was based on the results of the Phase III TROPION-Breast01 trial which showed a 37% reduction in the risk of disease progression or… Read More

#News #Regulatory

FDA
#AstraZeneca #FDA #Lymphoma #Oncology

First US approval for first-line BTK inhibitor for mantle cell lymphoma

The US Food and Drug Administration (FDA) has granted approval to acalabrutinib (Calquence) with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).  The regulator also granted approval to acalabrutinib as a single agent for adults with… Read More

#News #Regulatory #Trending News

Cancer cells
#AstraZeneca #Cancer research #Guide #Immune response #Immuno-oncology #Immunotherapy #Immutep #Interview #Oncology #OncologyCancer research

Podcast: Breakthroughs and opportunities in cancer research

This is the latest episode of the free DDW narrated podcast, titled “Where are the global breakthroughs, opportunities and developments in cancer research?”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “Global breakthroughs in cancer drug discovery”, “… Read More

#News

Woman reaches for inhaler
#Asthma #AstraZeneca #King's College London #Phase II trial

First new treatment for asthma attacks in 50 years

An injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further treatment by 30%, according to a UK study.  The findings, published in The Lancet Respiratory Medicine, could… Read More

#News #Trending News

Stamp of approval
#AstraZeneca #European Commission #Phase III trial #Rare disease

EU approves new indication for AstraZeneca’s Fasenra

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated vasculitis that can result in damage to multiple organs, and without treatment, can be fatal. The approval by… Read More

#News #Regulatory

The European Medicines Agency in Amsterdam
#AstraZeneca #CHMP #European Medicines Agency #Rare disease

EU CHMP recommends new indication for AZ’s benralizumab

AstraZeneca’s Fasenra (benralizumab) has been recommended for approval in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated vasculitis that can result in damage to multiple organs, and without treatment, can be fatal. If… Read More

#News #Regulatory

Human heart
#AstraZeneca #Clinical trials #ESC Congress #Heart failure

AstraZeneca provides updates at the ESC Congress

At this year’s annual European Society of Cardiology conference (ESC Congress 2024), which took place from 30 August – 2 September, AstraZeneca presented research that spans 38 abstracts, focusing on unmet need in heart failure (HF) and transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), and other chronic diseases.  Data highlights… Read More

#News